Caricamento...
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
ABP 501 [United States: AMJEVITA™ (adalimumab-atto); European Union: AMGEVITA(®) (adalimumab)] is the first approved biosimilar to adalimumab [reference product (RP)], a monoclonal antibody (mAb) targeting tumor necrosis factor-alfa (TNF-α). ABP 501 has received approval for use in indications that...
Salvato in:
| Pubblicato in: | Adv Ther |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Healthcare
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6822859/ https://ncbi.nlm.nih.gov/pubmed/31183781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00979-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|